Drug Database
SO

Sonovue (Lumason / Sonovue / BR1)

✓ Approved

Bracco · 小分子 · 小分子

什么是 Sonovue?

Sonovue 是一种小分子,由Bracco研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Lumason, Sonovue, BR1
公司Bracco
药物类别小分子, 影像药物
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

Sonovue 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersArteriosclerosis coronary artery✓ Approved
InvestigationsBlood pressure increased✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedThe Journal of chemical physics2026-09-10

Hierarchical Bayesian calibration of mesoscopic models for ultrasound contrast agents from force spectroscopy data.

Benvegnen Brieuc B, Ntarakas Nikolaos N, Potisk Tilen T, Pagonabarraga Ignacio I et al.

Ultrasound-guided drug and gene delivery (USDG) is a promising non-invasive approach for targeted therapeutic applications. Mechanical properties of encapsulated microbubbles (EMBs), which serve as contrast agents, affect their interactions with ultrasound and are, thus, critical to the success of USDG. Accurate calibration of particle-based EMB models is challenging as Bayesian inference with dissipative particle dynamics is prohibitively computationally expensive. We employ a surrogate-accelerated Bayesian calibration workflow that combines deep neural network surrogates and polynomial surrogates, transitional Markov chain Monte Carlo sampling, and hierarchical regularization across EMB diameters. Using this framework, we construct data-informed models of the commercial agents Definity and SonoVue and infer their force field parameters from published compression, indentation, and acoustic experiments. The presented methodology can be used to derive bespoke, data-informed models for a wide range of contrast agents, including gas vesicles, EMBs with diverse capsids consisting of lipids, proteins, or polymers, and functionalized with ligands.

PMID 42720223
阅读全文 →
PubMedMedicina clinica2026-08-25

Feasibility and characteristics of contrast-enhanced lung ultrasound in the diagnosis of pulmonary embolism in hospitalized patients.

Tung-Chen Yale Y, González Cecilio Juan Ignacio JI, Ferrer-Reyes Guillermo G, Gómez-Rojas Maria Agustina MA et al.

Lung ultrasound (LUS) is a complementary tool in pulmonary embolism (PE) when computed tomography pulmonary angiography (CTPA) is delayed or contraindicated. Contrast-enhanced ultrasound (CEUS) enables real-time perfusion assessment and may help characterize subpleural consolidations. We aimed to describe the feasibility and findings of LUS/CEUS in hospitalized PE and to explore the association between enhancement patterns and atelectasis. Retrospective single-center study (September-December 2025) including Internal Medicine inpatients with a final diagnosis of PE and reference imaging (CTPA and/or V/Q scintigraphy). CEUS was performed with SonoVue®; enhancement was classified as absent, heterogeneous, or homogeneous/hyperenhancing. Descriptive analyses and exploratory Fisher's exact tests were performed in the subgroup with consolidations evaluable by CEUS. Thirty-four patients were included (38.2% women). CTPA was performed in 33/34 and was positive in 32; two V/Q scans were performed, both high probability. LUS detected subpleural consolidations in 28/34 (82.4%), with a median of 2lesions per patient; localized pleural effusion was found in 24/33 (72.7%). CEUS was performed in 28/33; among patients with consolidation and CEUS (n=28), absent enhancement predominated (64.3%), followed by heterogeneous enhancement (25.0%) and homogeneous/hyperenhancement (10.7%). Homogeneous/hyperenhancement was associated with atelectasis (P=.017), whereas absent enhancement was associated with less atelectasis (P=.026). LUS and CEUS were feasible in hospitalized patients with PE, and CEUS provided additional perfusion information for characterizing subpleural consolidations.

PMID 42641494
阅读全文 →
PubMedJournal of pediatric surgery2026-08-09

Contrast-enhanced Colonosonography in AnoRectal malformations (CoCo-ARM) study.

Westwood Esther E, Bhardwaj Andrea A, Lloyd Clare C, Urquia Arlen A et al.

Fluoroscopic colostography (FC) is the gold-standard modality to plan definitive surgery in anorectal malformation (ARM). Contrast-enhanced colosonography (CeCS) can be used in this context. We conducted a prospective, single-centre study comparing the accuracy of CeCS with FC. Male patients with ARM awaiting reconstructive surgery were recruited during a 12-month period. CeCS using SonoVue were performed and reported contemporaneously by two investigating consultant radiologists. FCs were performed departmentally. All studies were reported as anonymised, unlinked studies by a third blinded consultant. The anonymised studies were reported with a Likert score to denote confidence in the findings. Findings were compared between the two imaging techniques and at operation. 11 patients were included. There was agreement in 8/11 (73%) patients between the two modalities. Beaking was seen at FC without a clear fistula in 2 cases, but was demonstrated clearly on CeCS. In the eleventh case, FC demonstrated a potential perineal fistula; there was poor filling of the distal limb using initial CeCS. This study was repeated under GA combined with cystoscopy, clearly identifying a recto-prostatic fistula. There was agreement in 100% of cases during blinded review of the CeCS with a mean Likert rating of 1.6 (SD = 0.64). In 10/10 (100%) of those who have undergone reconstructive surgery, CeCS findings were consistent with operative findings. CeCS is equivalent, if not superior to, FC in accurately identifying the fistular anatomy in males with anorectal malformations. Studies can be reviewed and reported with a high degree of diagnostic confidence.

PMID 42551510
阅读全文 →
PubMedJournal of ultrasound2026-07-28

Diagnostic accuracy of contrast-enhanced ultrasound versus duplex ultrasound and computed tomography angiography for endoleak detection after EVAR: a prospective comparative study.

Lustre Wellington Gianoti WG, Leal Libnah L, Cardoso Vinicius V, Cristino Mateus Aves Borges MAB et al.

Lifelong imaging surveillance after endovascular aneurysm repair (EVAR) is essential for endoleak detection but is limited by cumulative radiation and nephrotoxicity from computed tomography angiography (CTA). Contrast-enhanced ultrasound (CEUS) has emerged as a promising alternative, although prospective comparative data remain limited. In this prospective, single-centre diagnostic accuracy study, 30 consecutive patients (mean age 78.5 ± 7.1 years; 70% male) undergoing EVAR follow-up were evaluated with duplex ultrasound (DUS), CEUS (SonoVue®), and CTA within a 30-day interval. CTA served as the reference standard. Diagnostic performance metrics were calculated with 95% confidence intervals (CIs) according to STARD recommendations. Endoleaks were identified in 11 patients (36.7%). CTA detected 8 cases (26.7%), CEUS 9 (30.0%), and DUS 4 (13.3%). CEUS demonstrated high sensitivity (87.5%; 95% CI 47.3-99.7%) and specificity (90.9%; 70.8-98.9%), with overall accuracy of 90.0% (73.5-97.9%). In contrast, DUS showed limited sensitivity (33.3%; 9.9-65.1%) despite perfect specificity (100%), yielding lower accuracy (73.3%). Inter-modality agreement was 83.3%. CEUS demonstrates high diagnostic accuracy for endoleak detection after EVAR and represents a robust, radiation-free alternative to CTA for longitudinal surveillance. Given its favourable safety profile and diagnostic performance, CEUS should be considered a first-line imaging modality in routine follow-up, with CTA reserved for equivocal findings or pre-interventional planning. These results support a paradigm shift toward CEUS-based surveillance strategies.

PMID 42509453
阅读全文 →
PubMedJournal of clinical ultrasound : JCU2026-06-29

Noninvasive Preoperative Assessment of Sentinel Lymph Node Metastasis in Breast Cancer Using Super-Resolution Ultrasound Microvascular Imaging.

Guo Ruifang R, Liu Xi X, Zhao Junfeng J, Hu Xiangdong X et al.

To develop and internally validate a super-resolution ultrasound microvascular imaging (SR-UMI) model for noninvasive preoperative prediction of sentinel lymph node (SLN) involvement in breast cancer and to assess incremental value over clinical variables. In this prospective single-center study (January-June 2025), 162 consecutive patients with pathologically confirmed breast cancer underwent contrast-enhanced SR-UMI of the primary tumor prior to axillary surgery and SLNB. SonoVue (2.4 mL) was administered as an antecubital venous bolus. Examinations were performed on an Ultimus 9E ultrasound system using a 5-15 MHz linear transducer at low MI (0.08). Three predictor sets were evaluated: clinical-only (9 variables), SR-UMI-only (98 features), and combined (107 predictors). Elastic net-regularized logistic regression (EN-LR) was prespecified as the primary model and evaluated using nested stratified cross-validation (outer 5-fold, inner 3-fold) with pooled out-of-fold (OOF) predictions, assessing discrimination, calibration, and decision-curve analysis (DCA). SLN involvement was present in 55/162 patients (34.0%). EN-LR achieved AUC 0.662, PR-AUC 0.471, and Brier 0.232 for clinical-only predictors; SR-UMI-only improved performance (AUC 0.800; PR-AUC 0.572; Brier 0.185). The combined model performed similarly (AUC 0.802; PR-AUC 0.574; Brier 0.185). At the Youden operating point (threshold 0.514), the combined model yielded sensitivity 0.782, specificity 0.766, PPV 0.632, and NPV 0.872. Bootstrap OOF comparisons showed significant AUC improvements for SR-UMI-only versus clinical-only and combined vs. clinical-only, whereas combined vs. SR-UMI-only was not significant. Calibration showed a negative intercept and slope > 1 (combined: -0.637, 1.270). DCA demonstrated higher net benefit for EN-LR than treat-all/treat-none across threshold probabilities 0.05-0.60. SR-UMI microvascular features enabled good internal-validation performance and significantly improved discrimination over clinical/biopsy variables. The combined model offered no meaningful gain over SR-UMI only. External validation with recalibration is warranted.

PMID 42366496
阅读全文 →
PubMedVeterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association2026-05-31

Renal Perfusion in Healthy Horses: A Feasibility Study With Contrast-Enhanced Ultrasound.

Salazar Diana Villa Verde DVV, Ferreira Marília Alves MA, Brito Pedro Henrique Salles PHS, Uscategui Ricardo Andrés Ramirez RAR et al.

This study assessed the feasibility of contrast-enhanced ultrasound (CEUS) for evaluating renal perfusion in horses and compared perfusion parameters between age groups. In a prospective study, eight healthy horses were divided into young (3-5 years, n = 4) and old (16-17 years, n = 4) groups. All animals underwent B-mode, Doppler ultrasonography, and CEUS of the right kidney after an intravenous bolus of SonoVue (0.02 mL/kg). Qualitative analysis assessed contrast kinetics, whereas quantitative parameters (peak intensity, time to peak [TP], area under the curve, and wash-out time) were obtained from time-intensity curves in the renal cortex and medulla. The technique was safely performed in all horses, and the 0.02 mL/kg dose proved optimal for achieving adequate renal enhancement and consistent quantitative measurements. Quantitative analysis revealed a significantly longer TP in the renal cortex of older horses compared to young ones (p = 0.03), suggesting an age-related reduction in perfusion velocity. No other parameters showed significant differences. CEUS proved to be a feasible and safe method for assessing renal perfusion in horses. The prolonged cortical TP in older animals indicates that CEUS may be a sensitive tool for detecting early, subclinical perfusion changes associated with aging, warranting further investigation in horses with renal disease.

PMID 42216711
阅读全文 →

注册免费账户还可查看另外 1289 篇文献

免费注册查看全部文献 →

了解更多Sonovue